DE602005024437D1 - Mrt-geführte photodynamische therapie gegen krebs - Google Patents
Mrt-geführte photodynamische therapie gegen krebsInfo
- Publication number
- DE602005024437D1 DE602005024437D1 DE602005024437T DE602005024437T DE602005024437D1 DE 602005024437 D1 DE602005024437 D1 DE 602005024437D1 DE 602005024437 T DE602005024437 T DE 602005024437T DE 602005024437 T DE602005024437 T DE 602005024437T DE 602005024437 D1 DE602005024437 D1 DE 602005024437D1
- Authority
- DE
- Germany
- Prior art keywords
- mri
- photodynamic therapy
- treatment
- disclosed
- laser energy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Laser Surgery Devices (AREA)
- Radiation-Therapy Devices (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63325504P | 2004-12-03 | 2004-12-03 | |
PCT/US2005/044012 WO2006060797A2 (en) | 2004-12-03 | 2005-12-02 | Mri guided photodynamic therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005024437D1 true DE602005024437D1 (de) | 2010-12-09 |
Family
ID=36565853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005024437T Active DE602005024437D1 (de) | 2004-12-03 | 2005-12-02 | Mrt-geführte photodynamische therapie gegen krebs |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090076571A1 (de) |
EP (1) | EP1830879B1 (de) |
JP (1) | JP2008522666A (de) |
KR (1) | KR20070086803A (de) |
AT (1) | ATE485836T1 (de) |
AU (1) | AU2005311560A1 (de) |
CA (1) | CA2589881A1 (de) |
DE (1) | DE602005024437D1 (de) |
WO (1) | WO2006060797A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5237821B2 (ja) | 2005-12-05 | 2013-07-17 | 日東電工株式会社 | ポリグルタミン酸−アミノ酸結合体および方法 |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
CN104800856A (zh) * | 2007-04-10 | 2015-07-29 | 日东电工株式会社 | 多功能聚谷氨酸盐药物载体 |
JP2010526917A (ja) * | 2007-05-09 | 2010-08-05 | 日東電工株式会社 | 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体 |
WO2009055542A1 (en) * | 2007-10-26 | 2009-04-30 | University Of Utah Research Foundation | Use of mri contrast agents for evaluating the treatment of tumors |
ES2627420T3 (es) * | 2009-06-12 | 2017-07-28 | Erasmus University Medical Center Rotterdam | Nanofotomedicamentos destinados al tratamiento fotodinámico del cáncer |
WO2013119957A1 (en) * | 2012-02-10 | 2013-08-15 | Aidan Research And Consulting, Llc | Weight reduction through inactivation of gastric orexigenic mediator producing cells |
TW201514188A (zh) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | 製備釓磷維塞三鈉單水合物之方法 |
CN114870014B (zh) * | 2022-05-18 | 2023-07-07 | 南京邮电大学 | 一种多功能抗肿瘤高分子药物及其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594136A (en) * | 1989-12-21 | 1997-01-14 | Pharmacyclics, Inc. | Texaphyrin solid supports and devices |
US6340461B1 (en) * | 1996-12-17 | 2002-01-22 | David Stephen Terman | Superantigen based methods and compositions for treatment of diseases |
DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
US6534040B2 (en) * | 1999-12-23 | 2003-03-18 | Health Research, Inc. | Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US20020197648A1 (en) * | 2001-05-02 | 2002-12-26 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
-
2005
- 2005-12-02 US US11/792,206 patent/US20090076571A1/en not_active Abandoned
- 2005-12-02 EP EP05853048A patent/EP1830879B1/de not_active Not-in-force
- 2005-12-02 JP JP2007544609A patent/JP2008522666A/ja not_active Withdrawn
- 2005-12-02 KR KR1020077014910A patent/KR20070086803A/ko not_active Application Discontinuation
- 2005-12-02 CA CA002589881A patent/CA2589881A1/en not_active Abandoned
- 2005-12-02 AU AU2005311560A patent/AU2005311560A1/en not_active Abandoned
- 2005-12-02 AT AT05853048T patent/ATE485836T1/de not_active IP Right Cessation
- 2005-12-02 WO PCT/US2005/044012 patent/WO2006060797A2/en active Application Filing
- 2005-12-02 DE DE602005024437T patent/DE602005024437D1/de active Active
Also Published As
Publication number | Publication date |
---|---|
AU2005311560A1 (en) | 2006-06-08 |
EP1830879B1 (de) | 2010-10-27 |
JP2008522666A (ja) | 2008-07-03 |
ATE485836T1 (de) | 2010-11-15 |
WO2006060797A2 (en) | 2006-06-08 |
EP1830879A2 (de) | 2007-09-12 |
WO2006060797A3 (en) | 2006-08-24 |
EP1830879A4 (de) | 2008-09-17 |
US20090076571A1 (en) | 2009-03-19 |
CA2589881A1 (en) | 2006-06-08 |
KR20070086803A (ko) | 2007-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005024437D1 (de) | Mrt-geführte photodynamische therapie gegen krebs | |
Dupont et al. | INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): study protocol for a phase I clinical trial | |
Beck et al. | Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IX | |
Bechet et al. | Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies | |
Celli et al. | Imaging and photodynamic therapy: mechanisms, monitoring, and optimization | |
Wang et al. | Theranostic agents for photodynamic therapy of prostate cancer by targeting prostate-specific membrane antigen | |
Kochneva et al. | Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials | |
Arumainayagam et al. | Photodynamic therapy for focal ablation of the prostate | |
Bulin et al. | Radiation dose‐enhancement is a potent radiotherapeutic effect of rare‐earth composite nanoscintillators in preclinical models of glioblastoma | |
Hirschberg et al. | Disruption of the blood–brain barrier following ALA‐mediated photodynamic therapy | |
Kawczyk-Krupka et al. | Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy—a review | |
Jin et al. | Nanoparticle‐Enabled Selective Destruction of Prostate Tumor Using MRI‐Guided Focal Photothermal Therapy | |
Zou et al. | Application of photodynamic therapy for liver malignancies | |
Shackley et al. | Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours | |
Bugaj | Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer-clinician’s insight | |
Vaidya et al. | Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment | |
JP2008522666A5 (de) | ||
Zhang et al. | Novel self‐assembled multifunctional nanoprobes for second‐near‐infrared‐fluorescence‐image‐guided breast cancer surgery and enhanced radiotherapy efficacy | |
Guan et al. | Recent progress in nanomedicine for melanoma theranostics with emphasis on combination therapy | |
Schaffer et al. | Treatment of cervix carcinoma FIGO IIIB with Photofrin II as a radiosensitizer: a case report | |
Saxton et al. | Laser photochemotherapy: a less invasive approach for treatment of cancer | |
Wang et al. | One Stone, Three Birds: Multifunctional Nanodots as “Pilot Light” for Guiding Surgery, Enhanced Radiotherapy, and Brachytherapy of Tumors | |
Fei et al. | High‐field magnetic resonance imaging of the response of human prostate cancer to Pc 4‐based photodynamic therapy in an animal model | |
Shliakhtsin et al. | Pharmacokinetics and biodistribution of Photolon®(Fotolon®) in intact and tumor-bearing rats | |
Komolibus et al. | Perspectives on interstitial photodynamic therapy for malignant tumors |